查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肝纖維化市場－全球與區域分析、區域分析與預測（2025-2035）
市場調查報告書
商品編碼
1818891

肝纖維化市場－全球與區域分析、區域分析與預測（2025-2035）

Liver Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

全球肝纖維化市場 - 分析與預測（2025-2035）

肝纖維化是一種進行性性肝病，其特徵是由於多種潛在疾病（包括肝炎、飲酒、肥胖和自體免疫疾病）引起的慢性肝損傷導致肝臟中疤痕組織的積聚。

當肝臟試圖自我修復損傷時，膠原蛋白和其他細胞外基質成分的過度生成會導致纖維化。如果不及時治療，肝纖維化可能會發展為肝硬化、慢性肝功能衰竭，甚至肝癌。肝纖維化的程度通常分為幾個階段，早期階段可逆，但晚期階段會導致永久性損傷。

目前，肝纖維化仍然是一個嚴重的健康問題，但診斷技術和治療方法的進步使得更有效的治療成為可能。抗纖維化療法，例如用於治療肝炎相關纖維化的抗病毒藥物和標靶纖維化途徑的藥物，已成為重要的治療選擇。肝臟移植是末期肝纖維化和肝硬化的唯一根治性治療方法，但受捐贈者來源的限制。

各種肝病的盛行率正在穩步上升，包括自體免疫肝炎、非酒精性脂肪性肝病 (NAFLD)、酒精性肝病、慢性乙型和丙型肝炎以及肝纖維化。這些疾病的進展往往導致肝纖維化，而肝纖維化在世界各地正變得越來越普遍。肝纖維化盛行率的上升預計將推動其治療市場的發展。主要風險因素，如慢性B型和C型肝炎、合併感染愛滋病毒/愛滋病以及肝臟移植後使用免疫抑制劑，導致對肝纖維化治療的需求不斷成長。根據美國國家生物技術資訊中心的一項研究，預計到 2023 年肝病將成為全球主要的健康問題，約佔全球死亡率的 4%。因此，全球肝纖維化患者數量的快速增加將進一步推動市場成長。

此外，我們對肝纖維化分子機制的日益深入理解也推動了標靶治療的發展。對特定纖維化路徑（例如TGF-BETA訊號傳導和免疫細胞在纖維化進展中的作用）的研究，已促成了有前景的治療藥物的發現。肝彈性成像和血液生物標記等非侵入性診斷工具促進了肝纖維化的早期發現，從而能夠更及時地進行干預並更好地管理疾病。

儘管取得了這些進展，肝纖維化市場仍面臨許多挑戰。其中一個主要障礙是缺乏核准的有效抗纖維化療法。雖然有多種候選藥物正在臨床試驗中，但核准用於治療肝纖維化（尤其是晚期）的藥物卻寥寥無幾。這導致重度肝纖維化和肝硬化患者的治療選擇出現空白。此外，肝纖維化疾病及其進展的複雜性，以及在非侵入性手術的情況下難以準確分期肝纖維化，使得診斷和治療都變得複雜。

另一個挑戰是治療費用高昂，尤其是肝臟移植和針對纖維化的新型生物製藥等先進療法。這些治療通常價格昂貴，給醫療保健系統和患者帶來經濟負擔，尤其是在醫療資源有限的開發中地區。

全球肝纖維化市場競爭激烈，Akero Therapeutics、Sagimet Biosciences、Inventiva Pharma、Novo Nordisk、Viking Therapeutics、Boston Pharmaceuticals、Aligos Therapeutics、Boehringer Ingelheim 和 89bio 等主要企業推動創新和市場成長。這些公司在開發可顯著改善患者預後的新治療方法處於領先地位。透過對研發 (R&D) 的策略性投資、擴大產品系列以及增加全球獲得最先進治療的機會，這些行業領導者正在塑造肝纖維化治療的未來並為市場動態成長做出貢獻。此外，擴展到新興市場並透過區域分銷網路加強其影響力是挖掘服務不足的患者群體的關鍵策略。這些策略使公司能夠加強其市場地位並加速競爭激烈的肝纖維化治療市場中的成長。

肝纖維化市場細分

細分1：按地區

  • 北美洲
  • 歐洲
  • 亞太地區

全球肝纖維化市場正經歷重大變革時期，新興趨勢正在重塑治療模式，推動市場成長。人工智慧 (AI) 與肝纖維化治療的結合，蘊藏著巨大的潛力，有望徹底改變診斷和治療方式。透過分析大量患者數據，包括影像、生物標記和基因訊息，AI 可以顯著提高早期準確診斷肝纖維化的能力。機器學習演算法已被開發用於解讀彈性成像和電腦斷層掃描等非侵入性檢查，從而能夠更快、更可靠地評估肝損傷，從而提高診斷速度並實現早期療育。

肝纖維化市場向新興地區的擴張代表著巨大的成長機遇，這得益於多種因素。隨著亞太、拉丁美洲和非洲部分地區醫療基礎設施的改善，肝纖維化治療的需求預計將上升。在這些地區，肝病的盛行率正在上升，尤其是肥胖、飲酒和肝炎等風險因素日益普遍。此外，這些地區的人口老化也導致慢性肝病和肝纖維化的發生率上升。

目錄

執行摘要

第1章全球肝纖維化市場：產業分析

  • 市場概況與生態系統
  • 流行病學分析
  • 主要市場趨勢
    • 影響分析
  • 監管狀況
  • 管道分析
  • 市場動態
    • 概述
    • 市場促進因素
    • 市場限制
    • 市場機遇

2. 全球肝纖維化市場（按地區）價值，2023-2035

  • 北美洲
    • 市場動態
    • 市場規模及預測
    • 北美肝纖維化市場（按國家/地區，百萬美元），2023-2035 年
  • 歐洲
    • 市場動態
    • 市場規模及預測
    • 歐洲肝纖維化市場（按國家分類，百萬美元），2023-2035 年
  • 亞太地區
    • 市場動態
    • 市場規模及預測
    • 亞太肝纖維化市場（按國家/地區，百萬美元），2023-2035 年

第3章：競爭格局與公司概況

  • 競爭格局
  • 公司簡介
    • Akero Therapeutics
    • Sagimet Biosciences
    • Boehringer Ingelheim
    • 89bio
    • Inventiva Pharma
    • Galmed Pharmaceuticals
    • Novo Nordisk A/S
    • Viking Therapeutics
    • Hepion Pharmaceuticals
    • Pfizer, Inc.
    • HighTide Biopharma
    • Boston Pharmaceuticals
    • Rivus Pharmaceuticals
    • Lipocine
    • Aligos Therapeutics
    • MediciNova
    • Eli Lilly and Company
    • 其他

第4章調查方法

Product Code: BHL3270SA

Global Liver Fibrosis Market, Analysis and Forecast: 2025-2035

Liver fibrosis is a progressive liver disease characterized by the accumulation of scar tissue in the liver, resulting from chronic liver damage due to various underlying conditions such as hepatitis, alcohol use, obesity, or autoimmune diseases. As the liver attempts to heal itself from injury, excessive collagen and other extracellular matrix components are produced, leading to fibrosis. If left untreated, liver fibrosis can progress to cirrhosis, chronic liver failure, or even liver cancer. The severity of liver fibrosis is often classified into stages, with early stages being reversible but more advanced stages leading to permanent damage.

While liver fibrosis is currently a significant health concern, advancements in diagnostic technologies and treatments are helping to manage the disease more effectively. Antifibrotic therapies, such as antivirals for hepatitis-related fibrosis and medications that target fibrosis pathways, are emerging as key treatment options. Liver transplantation remains the only definitive cure for end-stage liver fibrosis or cirrhosis, though it is limited by donor availability.

The prevalence of various liver diseases, including autoimmune hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, chronic hepatitis B and C, and liver fibrosis, is steadily increasing. As these conditions progress, they often lead to liver fibrosis, which is becoming more common globally. The growing incidence of liver fibrosis is expected to drive the market for its treatment. Key risk factors such as chronic hepatitis B or C, co-infection with HIV/AIDS, and the use of immunosuppressive drugs following liver transplantation are contributing to the rising demand for liver fibrosis treatments. According to a study by the National Center for Biotechnology Information, liver disease is projected to become a major global health issue in 2023, contributing to an estimated 4% of global mortality. Thus, the worldwide surge in liver fibrosis cases is further propelling market growth.

Additionally, the growing understanding of the molecular mechanisms involved in liver fibrosis is fuelling the development of targeted therapies. Research into specific fibrosis pathways, such as TGF-B signaling and the role of immune cells in fibrosis progression, has led to the discovery of promising therapeutic agents. Non-invasive diagnostic tools, such as liver elastography and blood biomarkers, are also making it easier to detect liver fibrosis early, enabling more timely intervention and better management of the disease.

Despite these advances, the liver fibrosis market faces several challenges. One significant hurdle is the lack of approved, effective antifibrotic therapies. While several drug candidates are in clinical trials, there are few approved therapies available to treat liver fibrosis, especially for advanced stages. This has led to a gap in treatment options for patients with severe fibrosis or cirrhosis. Moreover, the complexity of the disease and its progression, along with the difficulty of accurately staging liver fibrosis without invasive procedures, complicates both diagnosis and treatment.

Another challenge is the high cost of treatment, particularly for advanced therapies such as liver transplantation and novel biologics targeting fibrosis. These treatments often come with high costs, placing financial strain on healthcare systems and patients, especially in developing regions where access to care may be limited.

The global liver fibrosis market is highly competitive, with several leading companies driving innovation and market growth, such as Akero Therapeutics, Sagimet Biosciences, Inventiva Pharma, Novo Nordisk, Viking Therapeutics, Boston Pharmaceuticals, Aligos Therapeutics, Boehringer Ingelheim, and 89bio. These companies are at the forefront of developing novel therapies that are significantly improving patient outcomes. Through strategic investments in research and development (R&D), expanding product portfolios, and increasing global access to cutting-edge treatments, these industry leaders are shaping the future of liver fibrosis care and contributing to the dynamic growth of the market. Additionally, expanding into emerging markets and increasing their presence through regional distribution networks are key strategies to tap into underserved patient populations. These strategies are enabling companies to strengthen their market position and accelerate growth in the competitive liver fibrosis treatment landscape.

Liver Fibrosis Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global liver fibrosis market is undergoing significant transformation, fueled by emerging trends that are reshaping treatment paradigms and driving liver fibrosis market growth. The integration of artificial intelligence (AI) into liver fibrosis treatment holds immense potential to revolutionize both diagnosis and treatment. AI can significantly enhance the ability to diagnose liver fibrosis early and accurately by analyzing vast amounts of patient data, including imaging, biomarkers, and genetic information. Machine learning algorithms are already being developed to interpret non-invasive tests like elastography and CT scans, offering faster and more reliable assessments of liver damage, which can improve the speed of diagnosis and allow for earlier intervention.

The expansion of the liver fibrosis market into emerging regions presents a significant growth opportunity due to several factors. As healthcare infrastructure improves in regions such as Asia-Pacific, Latin America, and parts of Africa, the demand for liver fibrosis treatments is expected to rise. These regions are witnessing an increasing prevalence of liver diseases, particularly as risk factors such as obesity, alcohol consumption, and hepatitis become more widespread. Furthermore, the aging population in these regions is leading to a higher incidence of chronic liver diseases and fibrosis.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Liver Fibrosis Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Liver Fibrosis Market (Region), Value ($Million), 2023-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Liver Fibrosis Market, by Country ($Million), 2023-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Liver Fibrosis Market, by Country ($Million), 2023-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Liver Fibrosis Market, by Country ($Million), 2023-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Akero Therapeutics.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Sagimet Biosciences.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Boehringer Ingelheim.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 89bio.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Inventiva Pharma.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Galmed Pharmaceuticals.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Novo Nordisk A/S.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Viking Therapeutics.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Hepion Pharmaceuticals.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Pfizer, Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 HighTide Biopharma.
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Boston Pharmaceuticals.
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Rivus Pharmaceuticals.
      • 3.2.13.1 Overview
      • 3.2.13.2 Top Products / Product Portfolio
      • 3.2.13.3 Top Competitors
      • 3.2.13.4 Target Customers/End-Users
      • 3.2.13.5 Key Personnel
      • 3.2.13.6 Analyst View
    • 3.2.14 Lipocine.
      • 3.2.14.1 Overview
      • 3.2.14.2 Top Products / Product Portfolio
      • 3.2.14.3 Top Competitors
      • 3.2.14.4 Target Customers/End-Users
      • 3.2.14.5 Key Personnel
      • 3.2.14.6 Analyst View
    • 3.2.15 Aligos Therapeutics.
      • 3.2.15.1 Overview
      • 3.2.15.2 Top Products / Product Portfolio
      • 3.2.15.3 Top Competitors
      • 3.2.15.4 Target Customers/End-Users
      • 3.2.15.5 Key Personnel
      • 3.2.15.6 Analyst View
    • 3.2.16 MediciNova.
      • 3.2.16.1 Overview
      • 3.2.16.2 Top Products / Product Portfolio
      • 3.2.16.3 Top Competitors
      • 3.2.16.4 Target Customers/End-Users
      • 3.2.16.5 Key Personnel
      • 3.2.16.6 Analyst View
    • 3.2.17 Eli Lilly and Company.
      • 3.2.17.1 Overview
      • 3.2.17.2 Top Products / Product Portfolio
      • 3.2.17.3 Top Competitors
      • 3.2.17.4 Target Customers/End-Users
      • 3.2.17.5 Key Personnel
      • 3.2.17.6 Analyst View
    • 3.2.18 Others

4. Research Methodology

List of Figures

  • Figure: Global Liver Fibrosis Market Coverage
  • Figure: Global Liver Fibrosis Market Key Trends, Impact Analysis, 2023-2035

List of Tables

  • Table: Global Liver Fibrosis Market Dynamics, Impact Analysis
  • Table: Global Liver Fibrosis Market (by Region), $Million, 2023-2035